This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Antibe Therapeutics Future Growth
Future criteria checks 0/6
Antibe Therapeutics is forecast to grow earnings and revenue by 27.2% and 67% per annum respectively while EPS is expected to grow by 27.2% per annum.
Key information
27.2%
Earnings growth rate
27.16%
EPS growth rate
Pharmaceuticals earnings growth
24.0%
Revenue growth rate
67.0%
Future return on equity
n/a
Analyst coverage
Low
Last updated
26 Apr 2024
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
DB:4B70 - Analysts future estimates and past financials data (CAD Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
3/31/2027
N/A
-25
N/A
N/A
1
3/31/2026
N/A
-24
N/A
N/A
1
3/31/2025
N/A
-15
N/A
N/A
1
3/31/2024
N/A
-20
N/A
N/A
2
12/31/2023
N/A
-18
-18
-18
N/A
9/30/2023
N/A
-18
-18
-18
N/A
6/30/2023
N/A
-19
-16
-16
N/A
3/31/2023
N/A
-19
-16
-16
N/A
12/31/2022
N/A
-21
-17
-17
N/A
9/30/2022
N/A
-22
-15
-15
N/A
6/30/2022
N/A
-24
-17
-17
N/A
3/31/2022
N/A
-25
-17
-17
N/A
12/31/2021
N/A
-26
6
6
N/A
9/30/2021
N/A
-26
1
1
N/A
6/30/2021
-1
-25
-1
-1
N/A
3/31/2021
N/A
-24
0
0
N/A
12/31/2020
2
-25
-22
-22
N/A
9/30/2020
5
-23
-18
-18
N/A
6/30/2020
8
-21
-13
-13
N/A
3/31/2020
10
-19
-11
-11
N/A
12/31/2019
10
-17
-9
-9
N/A
9/30/2019
10
-16
-8
-8
N/A
6/30/2019
10
-13
-7
-7
N/A
3/31/2019
10
-13
-7
-7
N/A
12/31/2018
9
-11
-8
-8
N/A
9/30/2018
9
-9
-8
-8
N/A
6/30/2018
9
-8
-7
-7
N/A
3/31/2018
9
-7
-7
-6
N/A
12/31/2017
9
-7
-6
-6
N/A
9/30/2017
8
-7
N/A
-5
N/A
6/30/2017
9
-6
N/A
-4
N/A
3/31/2017
9
-6
N/A
-3
N/A
12/31/2016
9
-5
N/A
-3
N/A
9/30/2016
9
-4
N/A
-3
N/A
6/30/2016
7
-4
N/A
-3
N/A
3/31/2016
4
-3
N/A
-3
N/A
12/31/2015
2
-3
N/A
-2
N/A
9/30/2015
N/A
-3
N/A
-2
N/A
6/30/2015
0
-3
N/A
-3
N/A
3/31/2015
N/A
-4
N/A
-4
N/A
12/31/2014
N/A
-5
N/A
-5
N/A
9/30/2014
N/A
-5
N/A
-4
N/A
6/30/2014
N/A
-4
N/A
-4
N/A
3/31/2014
N/A
-3
N/A
-3
N/A
12/31/2013
N/A
-2
N/A
-2
N/A
9/30/2013
N/A
-1
N/A
-2
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4B70 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 4B70 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 4B70 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 4B70 is forecast to have no revenue next year.
High Growth Revenue: 4B70 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 4B70's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2024/05/28 07:42
End of Day Share Price
2024/04/10 00:00
Earnings
2023/12/31
Annual Earnings
2023/03/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Antibe Therapeutics Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.